Neuroprotective potential of erythropoietin and its derivative carbamylated erythropoietin in periventricular leukomalacia

Experimental Neurology

Volumn 230, Issue 2, 2011, Pages 227-239

  Liu, Wei ^a   Shen, Yan ^a   Plane, Jennifer M ^a   Pleasure, David E ^a,b   Deng, Wenbin ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b Institute for Pediatric Regenerative Medicine   (United States)

Author keywords

Carbamylated erythropoietin; Erythropoietin; Hypoxia ischemia; Lipopolysaccharide; Microglia; Oligodendrocyte; PARP 1; Periventricular leukomalacia; White matter injury

Indexed keywords

CARBAMYLATED ERYTHROPOIETIN; ERYTHROPOIETIN; MYELIN; NEUROPROTECTIVE AGENT; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE 1; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL ACTIVATION; CELL DAMAGE; CELL MATURATION; CONTROLLED STUDY; DRUG MECHANISM; ENCEPHALOMALACIA; ENZYME ACTIVITY; MICROGLIA; MOUSE; MYELINATION; NEUROPROTECTION; NONHUMAN; OLIGODENDROGLIA; PRIORITY JOURNAL; PROTEIN DEPLETION; SINGLE DRUG DOSE;

ANIMALS; ANOXIA; BRAIN; BRAIN ISCHEMIA; DISEASE MODELS, ANIMAL; ERYTHROPOIETIN; HUMANS; INFANT, NEWBORN; INFLAMMATION; LEUKOMALACIA, PERIVENTRICULAR; MICE; MICROGLIA; MYELIN SHEATH; NEURONS; NEUROPROTECTIVE AGENTS; OLIGODENDROGLIA;

EID: 79958746580     PISSN: 00144886     EISSN: 10902430     Source Type: Journal    
DOI: 10.1016/j.expneurol.2011.04.021     Document Type: Article

References (67)

1. Agresti C., D'Urso D., Levi G. Reversible inhibitory effects of interferon-γ and tumor necrosis factor-α on oligodendroglial lineage cell proliferation and differentiation in vitro. Eur. J. Neurosci. 1996, 8:1106-1116.
2. Billiards S.S., Haynes R.L., Folkerth R.D., Trachtenberg F.L., Liu L.G., Volpe J.J., Kinney H.C. Development of microglia in the cerebral white matter of the human fetus and infant. J. Comp. Neurol. 2006, 497:199-208.
3. Brines M.L., Ghezzi P., Keenan S., Agnello D., de Lanerolle N.C., Cerami C., Itri L.M., Cerami A. Erythropoietin crosses the blood-brain barrier to protect against experimental brain injury. Proc. Natl Acad. Sci. 2000, 97:10526-10531.
4. Buemi M., Cavallaro E., Floccari F., Sturiale A., Aloisi C., Trimarchi M., Corica F., Frisina N. The pleiotropic effects of erythropoietin in the central nervous system. J. Neuropathol. Exp. Neurol. 2003, 62:228-236.
5. Buntinx M., Moreels M., Vandenabeele F., Lambrichts I., Raus J., Steels P., Stinissen P., Ameloot M. Cytokine-induced cell death in human oligodendroglial cell lines: I. Synergistic effects of IFN-gamma and TNF-alpha on apoptosis. J. Neurosci. Res. 2004, 76:834-845.
6. Burkle A. Poly (ADP-ribose). The most elaborate metabolite of NAD+. FEBS J. 2005, 272:4576-4589.
7. Chiarugi A., Moskowitz M.A. Poly (ADP-ribose) polymerase-1 activity promotes NF-kappaB-driven transcription and microglial activation: implication for neurodegenerative disorders. J. Neurochem. 2003, 85:306-317.
8. Csete M., Rodriguez L., Wilcox M., Chadalavada S. Erythropoietin receptor is expressed on adult rat dopaminergic neurons and erythropoietin is neurotrophic in cultured dopaminergic neuroblasts. Neurosci. Lett. 2004, 359:124-126.
9. Dammann O., Kuban K.C., Leviton A. Perinatal infection, fetal inflammatory response, white matter damage, and cognitive limitations in children born preterm. Ment. Retard. Dev. Disabil. Res. Rev. 2002, 8:46-50.
10. Deng W. Neurobiology of injury to the developing brain. Nat. Rev. Neurol. 2010, 6(6):328-336.
11. Deng W., Pleasure J., Pleasure D. Progress in periventricular leukomalacia. Arch. Neurol. 2008, 65:1291-1295.
12. Follett P.L., Rosenberg P.A., Volpe J.J., Jensen F.E. NBQX Attenuates excitotoxic injury in developing white matter. J. Neurosci. 2000, 20:9235-9241.
13. Follett P.L., Deng W., Dai W., Talos D.M., Massillon L.J., Rosenberg P.A., Volpe J.J., Jensen F.E. Glutamate receptor-mediated oligodendrocyte toxicity in periventricular leukomalacia: a protective role for topiramate. J. Neurosci. 2004, 24:4412-4420.
14. Garcia J.H., Wagner S., Liu K.F., Hu X.J. Neurological deficit and extent of neuronal necrosis attributable to middle cerebral artery occlusion in rats. Statistical validation. Stroke 1995, 26:627-634.
15. Goncalves L.F., Chaiworapongsa T., Romero R. Intrauterine infection and prematurity. Ment. Retard. Dev. Disabil. Res. Rev. 2002, 8:3-13.
16. Gonzalez F.F., McQuillen P., Mu D., Chang Y., Wendland M., Vexler Z., Ferriero D.M. Erythropoietin enhances long-term neuroprotection and neurogenesis in neonatal stroke. Dev. Neurosci. 2007, 29(4-5):321-330.
17. Gonzalez F.F., Abel R., Almli C.R., Mu D., Wendland M., Ferriero D.M. Erythropoietin sustains cognitive function and brain volume after neonatal stroke. Dev. Neurosci. 2009, 31(5):403-411. Epub 2009 Aug 11. PubMed PMID: 19672069; PubMed Central PMCID: PMC2820334.
18. Grasso G., Sfacteria A., Meli F., Passalacqua M., Fodale V., Buemi M., Giambartino F., Lacopino D.G., Tomasello F. The role of erythropoietin in neuroprotection: therapeutic perspectives. Drug News Perspect. 2007, 20:315-320.
19. Hamby A.M., Sun S.W., Kauppinen T.M., Swanson R.A. Use of a poly (ADP-ribose) polymerase inhibitor to suppress inflammation and neuronal death after cerebral ischemia-reperfusion. Stroke 2007, 38:632-636.
20. Huber A., Bai P., de Murcia J.M., de Murcia G. PARP-1, PARP-2 and ATM in the DNA damage response: functional synergy in mouse development. DNA Repair 2004, 3:1103-1108.
21. Iwai M., Cao G., Yin W., Stetler R.A., Liu J., Chen J. Erythropoietin promotes neuronal replacement through revascularization and neurogenesis after neonatal hypoxia/ischemia in rats. Stroke 2007, 38(10):2795-2803. Oct, Epub 2007 Aug 16. PubMed PMID: 17702962.
22. Iwai M., Stetler R.A., Xing J., Hu X., Gao Y., Zhang W., Chen J., Cao G. Enhanced oligodendrogenesis and recovery of neurological function by erythropoietin after neonatal hypoxic/ischemic brain injury. Stroke 2010, 41(5):1032-1037. May, Epub 2010 Apr 1. PubMed PMID: 20360553; PubMed Central PMCID: PMC2919308.
23. Jagtap P., Szabo C. Poly (ADP-ribose) polymerase and the therapeutic effects of its inhibitors. Nat. Rev. Drug Discov. 2005, 4:421-440.
24. Kauppinen T.M., Swanson R.A. Poly (ADP-ribose) polymerase-1 promotes microglial activation, proliferation, and matrix metalloproteinase-9-mediated neuron death. J. Immunol. 2005, 174:2288-2296.
25. Khwaja O., Volpe J.J. Pathogenesis of cerebral white matter injury of prematurity. Arch Dis Child Fetal Neonatal Ed 2008, 153-161. 93 Edition.
26. Kreutzberg G.W. Microglia: a sensor for pathological events in the CNS. Trends Neurosci. 1996, 19:312-318.
27. Leist M., Ghezzi P., Grasso G., Bianchi R., Villa P., Fratelli M., Savino C., Bianchi M., Nielsen J., Gerwien J., Kallunki P., Larsen A.K., Helboe L., Christensen S., Pedersen L.O., Nielsen M., Torup L., Sager T., Sfacteria A., Erbayraktar S., Erbayraktar Z., Gokmen N., Yilmaz O., Cerami-Hand C., Xie Q.W., Coleman T., Cerami A., Brines M. Derivatives of erythropoietin that are tissue protective but not erythropoietic. Science 2004, 305:239-242.
28. Lescot T., Fulla-Oller L., Palmier B., Po C., Beziaud T., Puybasset L., Plotkine M., Gillet B., Meric P., Marchand-Leroux C. Effect of acute poly(ADP-ribose) polymerase inhibition by 3-AB on blood-brain barrier permeability and edema formation after focal traumatic brain injury in rats. J. Neurotrauma 2010, 27:1069-1079.
29. Li J., Baud O., Vartanian T., Volpe J.J., Rosenberg P.A. Peroxynitrite generated by inducible nitric oxide synthase and NADPH oxidase mediates microglial toxicity to oligodendrocytes. Proc. Natl Acad. Sci. 2005, 102:9936-9941.
30. Li X., Klaus J.A., Zhang J., Xu Z., Kibler K.K., Andrabi S.A., Rao K., Yang Z.J., Dawson T.M., Dawson V.L., Koehler R.C. Contributions of poly(ADP-ribose) polymerase-1 and -2 to nuclear translocation of apoptosis-inducing factor and injury from focal cerebral ischemia. J. Neurochem. 2010, 113:1012-1022.
31. Lykissas M.G., Korompillias A.V., Vekris M.D., Mitsionis G.I., Sakellariou E., Beris A.E. The role of erythropoietin in central and peripheral nerve injury. Clin. Neurol. Neurosurg. 2007, 109:639-644.
32. Mahmood A., Lu D., Qu C., Goussev A., Zhang Z.G., Lu C., Chopp M. Treatment of traumatic brain injury in rats with erythropoietin and carbamylated erythropoietin. J. Neurosurg. 2007, 107:392-397.
33. Marti H.H., Wenger R.H., Rivas L.A., Straumann U., Digicaylioglu M., Henn V., Yonekawa Y., Bauer C., Gassmann M. Erythropoietin gene expression in human, monkey and murine brain. Eur. J. Neurosci. 1996, 8:666-676.
34. Martin J.A., Kung H.C., Mathewsa T.J., Hoyert D.L., Strobino D.M., Guyer B., Sutton S.R. Annual summary of vital statistics: 2006. Pediatrics 2008, 121:788-801.
35. McPherson R.J., Juul S.E. Erythropoietin for infants with hypoxic-ischemic encephalopathy. Curr. Opin. Pediatr. 2010, 22(2):139-145. Apr, Review. PubMed PMID: 20090525; PubMed Central PMCID: PMC2879270.
36. Milano M., Collomp R. Erythropoietin and neuroprotection: a therapeutic perspective. J. Oncol. Pharm. Pract. 2005, 11:145-149.
37. Montero M., Poulsen F.R., Noraberg J., Kirkeby A., van Beek J., Leist M., Zimmer J. Comparison of neuroprotective effects of erythropoietin (EPO) and carbamylerythropoietin (CEPO) against ischemia-like oxygen-glucose deprivation (OGD) and NMDA excitotoxicity in mouse hippocampal slice cultures. Exp. Neurol. 2007, 204:106-117.
38. Nakajima H., Nagaso H., Kakui N., Ishikawa M., Hiranuma T., Hoshiko S. Critical role of the automodification of poly (ADP-ribose) polymerase-1 in nuclear factor-kappaB-dependent gene expression in primary cultured mouse glial cells. J. Biol. Chem. 2004, 279:42774-42786.
39. Olson J.K., Miller S.D. Microglia initiate central nervous system innate and adaptive immune responses through multiple TLRs. J. Immunol. 2004, 173:3916-3924.
40. Pang Y., Cai Z.W., Rhodes P.G. Effects of tumor necrosis factor-alpha on developing optic nerve oligodendrocytes in culture. J. Neurosci. Res. 2005, 80:226-234.
41. Platt M.J., Cans C., Johnson A., Surman G., Topp M., Torrioli M.G., Krageloh-Mann I. Trends in cerebral palsy among infants of very low birth weight (<1500g) or born prematurely (<32weeks) in 16 European centres: a database study. Lancet 2007, 369:43-50.
42. Poltorak A., He X., Smirnova I., Liu M.Y., Van Huffel C., Du X., Birdwell D., Alejos E., Silva M., Galanos C., Freudenberg M., Ricciardi-Castagnoli P., Layton B., Beutler B. Defective LPS signaling in C3H/HeJ and C57BL/10ScCr mice: mutations in Tlr4 gene. Science 1998, 282:2085-2088.
43. Qureshi S.T., Lariviere L., Leveque G., Clermont S., Moore K.J., Gros P., Malo D. Endotoxin-tolerant mice have mutations in Toll-like receptor 4 (Tlr4). J. Exp. Med. 1999, 189:615-625.
44. Rees S., Hale N., De Matteo R., Cardamone L., Tolcos M., Loeliger M., Mackintosh A., Shields A., Probyn M., Greenwood D., Harding R. Erythropoietin is neuroprotective in a preterm ovine model of endotoxin-induced brain injury. J. Neuropathol. Exp. Neurol. 2010, 69(3):306-319. Mar.
45. Rivest S. Molecular insights on the cerebral innate immune system. Brain Behav. Immun. 2003, 17:13-19.
46. Sasaki R. Pleiotropic functions of erythropoietin. Intern. Med. 2003, 42:142-149.
47. Segovia K.N., McClure M., Moravec M., Luo N.L., Wan Y., Gong X., Riddle A., Craig A., Struve J., Sherman L.S., Back S.A. Arrested oligodendrocyte lineage maturation in chronic perinatal white matter injury. Ann. Neurol. 2008, 63:520-530.
48. Smith S. The world according to PARP. Trends Biochem. Sci. 2001, 26:174-179.
49. Susin S.A., Lorenzo H.K., Zamzami N., Marzo I., Snow B.E., Brothers G.M., Mangion J., Jacotot E., Costantini P., Loeffler M., Larochette N., Goodlett D.R., Aebersold R., Siderovski D.P., Penninger J.M., Kroemer G. Molecular characterization of mitochondrial apoptosis-inducing factor. Nature 1999, 397:441-446.
50. Tomimatsu T., Fukuda H., Endoh M., Mu J., Watanabe N., Kohzuki M., Fujii E., Kanzaki T., Oshima K., Doi K., Kubo T., Murata Y. Effects of neonatal hypoxic-ischemic brain injury on skilled motor tasks and brainstem function in adult rats. Brain Res. 2002, 926:108-117.
51. Ullrich O., Diestel A., Eyupoglu I.Y., Nitsch R. Regulation of microglial expression of integrins by poly (ADP-ribose) polymerase-1. Nat. Cell Biol. 2001, 3:1035-1042.
52. Ullrich O., Diestel A., Bechmann I., Homberg M., Grune T., Hass R., Nitsch R. Turnover of oxidatively damaged nuclear proteins in BV-2 microglial cells is linked to their activation state by poly-ADP-ribose polymerase. FASEB J. 2001, 15:1460-1462.
53. Van der Kooij M.A., Groenendaal F., Kavelaars A., Heijnen C.J., van Bel F. Neuroprotective properties and mechanisms of erythropoietin in in vitro and in vivo experimental models for hypoxia/ischemia. Brain Res. Rev. 2008, 59:22-33.
54. Veto S., Acs P., Bauer J., Lassmann H., Berente Z., Setalo G.J., Borgulya G., Sumegi B., Komoly S., Gallyas F.J., Illes Z. Inhibiting poly (ADP-ribose) polymerase: a potential therapy against oligodendrocyte death. Brain 2010, 133:822-834.
55. Villa P., Bigini P., Mennini T., Agnello D., Laragione T., Cagnotto A., Viviani B., Marinovich M., Cerami A., Coleman T.R., Brines M., Ghezzi P. Erythropoietin selectively attenuates cytokine production and inflammation in cerebral ischemia by targeting neuronal apoptosis. J. Exp. Med. 2003, 198:971-975.
56. Villa P., van Beek J., Larsen A.K., Gerwien J., Christensen S., Cerami A., Brines M., Leist M., Ghezzi P., Torup L. Reduced functional deficits, neuroinflammation, and secondary tissue damage after treatment of stroke by nonerythropoietic erythropoietin derivatives. J. Cereb. Blood Flow Metab. 2007, 27:552-563.
57. Virág L., Szabó C. The therapeutic potential of poly (ADP-ribose) polymerase inhibitors. Pharmacol. Rev. 2002, 54:375-429.
58. Volpe J.J. Neurobiology of periventricular leukomalacia in the premature infant. Pediatr. Res. 2001, 50:553-562.
59. Volpe J.J. Cerebral white matter injury of the premature infant - more common than you think. Pediatrics 2003, 112:176-180.
60. Volpe J.J. Encephalopathy of prematurity includes neuronal abnormalities. Pediatrics 2005, 116:221-225.
61. Volpe J.J. Brain injury in premature infants: a complex amalgam of destructive and developmental disturbances. Lancet Neurol. 2009, 8(1):110-124.
62. Wang L., Zhang Z., Wang Y., Zhang R., Chopp M. Treatment of stroke with erythropoietin enhances neurogenesis and angiogenesis and improves neurological function in rats. Stroke 2004, 35:1732-1737.
63. Wang Y., Zhang Z.G., Rhodes K., Renzi M., Zhang R.L., Kapke A., Lu M., Pool C., Heavner G., Chopp M. Postischemic treatment with erythropoietin or carbamylated erythropoietin reduces infarction and improves neurological outcome in a rat model of focal cerebral ischemia. Br. J. Pharmacol. 2007, 151:1377-1384.
64. Wei L., Han B.H., Li Y., Keogh C.L., Holtzman D.M., Yu S.P. Cell death mechanism and protective effect of erythropoietin after focal ischemia in the whisker-barrel cortex of neonatal rats. J. Pharmacol. Exp. Ther. 2006, 317:109-116.
65. Ye H., Cande C., Stephanou N.C., Jiang S., Gurbuxani S., Larochette N., Daugas E., Garrido C., Kroemer G., Wu H. DNA binding is required for the apoptogenic action of apoptosis inducing factor. Nat. Struct. Biol. 2002, 9:680-684.
66. Yu S.W., Wang H., Poitras M.F. Mediation of poly (ADP-ribose) polymerase-1-dependent cell death by apoptosis-inducing factor. Science 2002, 297:259-263.
67. Yu S.W., Wang H., Dawson T.M., Dawson V.L. Poly (ADP-ribose) polymerase-1 and apoptosis inducing factor in neurotoxicity. Neurobiol. Dis. 2003, 14:303-317.